Full Length Research Paper
References
|
Bergner R. Diel IJ, Henrich D, Hoffmann M, Uppenkamp M (2006). Differences in nephrotoxicity of intravenous bisphosphonates for the treatment of malignancy-related bone disease. Onkologie 29(11):534-40. Crossref |
||||
| Benowitz S (2013). SCO Issues Updated Guideline on the Role of Bone-Modifying Agents in the Prevention and Treatment of Bone Metastases in Patients with Metastatic Breast Cancer. Available at http://www.asco.org/press-center/asco-issues-updated-guideline-role-bone-modifying-agents-prevention-and-treatment-bone | ||||
|
Cortas N, Nakid WN (1990). Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method. Clin. Chem. 36(8):1440-1443. Pubmed |
||||
| Fairbanks V, Klee GG (1986): Biochemical aspects of hematology. In: Tietz NW (Ed), Textbook of clinical chemistry. WB Saunders, Philadelphia. pp. 1532-1534. | ||||
|
Karabulut AB, Gül M, Karabulut E, Kiran TR, Ocak SG, Otlu O (2010). Oxidantand antioxidant activity in rabbit livers treated with zoledronic acid. Transpl. Proc. 42:3820-2. Crossref |
||||
|
Liu J, Zheng L, Zhang W, Chang K, Pang Y (2013). A Modified method for reducing renal injury in zoledronic acid treatment of hypercalcemia and adverse skeletal events. Indian J. Palliat. Care 19(1):58-63. Crossref |
||||
|
Markowitz GS, Fine PL, Stack JI (2003). Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. 64:281–289. Crossref |
||||
|
Mihara M, Uchiyama M (1978). Determination of malonaldehyde precur-sor in tissues by thiobarbituric acid test. Analyt. Biochem. 86(1):271-227. Crossref |
||||
|
Ott SM (2012). Bisphosphonate safety and efficacy in chronic kidney disease. Kidney Int. 82(1):833 – 835. Crossref |
||||
|
Pfister T, Atzpodien E, Bauss F (2003). The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. Toxicology, 191:159–167. Crossref |
||||
|
Pfister T, Atzpodien E, Bohrmann B (2005). Acute nephrotoxicity of three intravenous bisphosphonates in the rat. Basic Clin. Pharmacol. Toxicol. 97:374-81. Crossref |
||||
|
Puertas MC, Martínez-Martos JM, Cobo MP, Carrera MP, Mayas MD, Ramírez-Expósito MJ (2012). Plasma oxidative stress parameters in men and women with early stage Alzheimer type dementia. Exp. Gerontol. 47(8):1165-116. Crossref |
||||
|
Schuster M, Borderie D, Grange AP, Lemarechal H, Kavian-Tessler N, Batteux F(2012). Oxidative stress markers are increased since early stages of infection in syphilitic patients. Arch. Dermatol. Res. 304:689–697. Crossref |
||||
|
Soki NF, Li X, Berry J, Koh A, Sinder P B (2013): The Effects of Zoledronic Acid in the Bone and Vasculature Support of Hematopoietic Stem Cell Niches. J. Cell. Biochem. 114:67–78 . Crossref |
||||
|
Tanvetyanon T, Stiff PJ (2006). Management of the adverse effects associated with intravenous bisphosphonates. Ann. Oncol. 17(6):897-907. Crossref |
||||
Copyright © 2025 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
